Partnership / Collaboration · GCC · Announced 9 Nov 2026
M42 → ADCAN Pharma
ADCAN Pharma and M42 signed an MoU at Abu Dhabi Future Health Summit 2026 to explore CDMO work through Glenmark, UAE registration of an ADC oncology product, and clinical-trial support for M42's CRO, IROS.
Parties: M42 (United Arab Emirates) → ADCAN Pharma (United Arab Emirates)
- Deal type
- Partnership / Collaboration
- Value
- Undisclosed
- Territory
- United Arab Emirates, with export markets
- Therapeutic area
- Oncology
- Assets
- ADC oncology product (not named); CDMO secondary packaging services
- Announced
- 9 Nov 2026
Our analysis
Why this matters
ADCAN Pharma, a UAE-based manufacturer, and M42, the Abu Dhabi health group built on AI, technology and genomics, signed a memorandum of understanding at Abu Dhabi Future Health Summit 2026 to explore collaboration in pharmaceutical manufacturing and clinical research. The announcement was published on 9 November 2026. It was signed by ADCAN CEO Dr. Fokion Sinis and Dr. David Kavanagh, Acting COO of M42's Integrated Health Solutions.
The MoU links three things: a contract manufacturing opportunity through Glenmark Pharmaceuticals, registration of an advanced antibody-drug conjugate (ADC) for cancer in the UAE, and support for clinical trials run by IROS, M42's contract research organization. Glenmark has already completed a quality audit of ADCAN's facility.
The full analysis is free to read with a work email on this page.
Source: Mid-East.Info